BA 2101
Alternative Names: Anti-IL4R antibody - Luye Pharma/ Shandong Boan Biotechnology; BA-2101; PR-103Latest Information Update: 05 Apr 2024
At a glance
- Originator Shandong Boan Biotechnology
- Developer Luye Pharma Group; Shandong Boan Biotechnology
- Class Anti-inflammatories; Antiallergics; Antiasthmatics; Monoclonal antibodies; Skin disorder therapies
- Mechanism of Action Interleukin 4 receptor alpha subunit antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Asthma; Atopic dermatitis; Pruritus; Sinusitis; Urticaria
- Discontinued Food hypersensitivity
Most Recent Events
- 05 Apr 2024 Phase-II clinical trials in Asthma in China (SC), prior to April 2024 (Shandong Boan Biotechnology pipeline, April 2024)
- 05 Apr 2024 Phase-II clinical trials in Atopic dermatitis in China (SC), prior to April 2024 (Shandong Boan Biotechnology pipeline, April 2024)
- 05 Apr 2024 Phase-II clinical trials in Pruritus in China (SC), prior to April 2024 (Shandong Boan Biotechnology pipeline, April 2024)